Skip to main content
Applied Therapeutics, Inc. logo

Applied Therapeutics, Inc. — Investor Relations & Filings

Ticker · APLT ISIN · US03828A1016 LEI · 549300KL3IJPHZM2GR04 US Manufacturing
Open in API
Filings indexed 491 across all filing types
Latest filing 2026-02-17 Major Shareholding Noti…
Country US United States of America
Listing US APLT

About Applied Therapeutics, Inc.

https://www.appliedtherapeutics.com/

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for rare diseases with high unmet medical needs. The company's pipeline is centered on creating transformative treatments by targeting validated molecular pathways. Its primary focus is on the development of aldose reductase inhibitors (ARIs) for a range of conditions. Key therapeutic areas include rare metabolic and central nervous system (CNS) diseases, such as Classic Galactosemia, Sorbitol Dehydrogenase (SORD) deficiency, and PMM2-CDG, as well as Diabetic Cardiomyopathy. The company's approach aims to accelerate the drug development timeline by utilizing biomarkers and established clinical endpoints.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
4 Filing
Director's Dealing
2026-02-04 English
4 Filing
Director's Dealing
2026-02-03 English
S-8 POS Filing
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment to multiple Form S-8 Registration Statements filed with the SEC. It discusses deregistration of securities following a merger, terminating the effectiveness of the registration statements and removing unsold securities from registration. The document is a regulatory filing related to securities registration and deregistration, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. It is a formal SEC filing about registration statement amendments and deregistration, fitting the category of Regulatory Filings (RNS).
2026-02-03 English
4 Filing
Director's Dealing
2026-02-03 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated February 3, 2026, by Applied Therapeutics, Inc. It details the completion of a merger transaction, including the tender offer, merger agreement, acquisition completion, change in control, delisting notice, and changes in directors and officers. The document includes detailed descriptions of the merger terms, tender offer results, and corporate governance changes resulting from the merger. It also includes a formal notice of delisting from Nasdaq and changes in control and management. The presence of multiple Items (2.01, 3.01, 5.01, 5.02) related to acquisition completion, delisting, change in control, and management changes indicates this is a current report on significant corporate events rather than a financial report or earnings release. The document is not an announcement of a report but a substantive filing reporting the merger and related corporate changes. Therefore, the most appropriate classification is a Regulatory Filing (RNS) as it covers multiple regulatory disclosures in one current report form 8-K, including merger completion, delisting, and management changes, but does not fit solely into M&A filings or delisting announcements alone due to its comprehensive nature and regulatory reporting format.
2026-02-03 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.